#Ireland #Dublin #Mallinckrodt #American Liver Foundation #Hepatorenal Syndrome

Mallinckrodt Champions Hepatorenal Syndrome Awareness Day

On October 14, 2025, Mallinckrodt plc, a renowned global specialty pharmaceutical company, announced its backing for the inaugural Hepatorenal Syndrome (HRS) Awareness Day. This significant initiative is established by the American Liver Foundation (ALF) and aims to observe an annual event during National Liver Awareness Month. The core mission is to elevate awareness and educate the public about HRS— a serious, life-threatening complication arising from advanced liver disease.

Hepatorenal Syndrome (HRS) is a medical condition characterized by severe renal failure, typically occurring in patients with liver diseases such as cirrhosis. It can manifest in two forms: the acute variant, known as HRS-acute kidney injury (AKI), which progresses quickly and necessitates hospitalization; and the chronic variant, or HRS-chronic kidney disease (CKD), that develops gradually over weeks to months. Reports indicate that over 60,000 Americans are affected annually by HRS, making it a rare condition affecting roughly 0.01% of the U.S. population, yet the incidence of hospitalizations due to HRS is on the rise.

Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Mallinckrodt, expressed pride in supporting this vital effort to spotlight HRS. He emphasized the importance of increasing visibility for the patients, healthcare teams, and professionals involved in caring for those afflicted with this condition. Throughout history, physicians in the U.S. have faced significant challenges regarding the effective treatment of patients suffering from HRS, highlighting the necessity for greater awareness and educational resources.

During National Liver Awareness Month, bringing attention to HRS is especially pertinent. Lorraine Stiehl, CEO of the American Liver Foundation, remarked on the importance of acknowledging this life-threatening complication and those who face its realities. The support provided by sponsors such as Mallinckrodt is invaluable, as it accelerates efforts to make treatment options accessible to patients in need, distinctly emphasizing the need for public awareness and recognition of HRS.

About Mallinckrodt

Mallinckrodt is committed to enhancing lives through the provision of therapeutic solutions tailored to address unmet patient needs. The company is widely recognized for its expertise in the manufacturing of high-quality generics, sterile injectables, and active pharmaceutical ingredients. Their operational structure involves multiple wholly owned subsidiaries, focusing on two key sectors: the Brands business, which specializes in treatments for autoimmune and rare diseases across various medical disciplines, including hepatology and nephrology, and the Par Health business, dealing with generic medications and sterile injectables.

In light of the acute nature of HRS and its ramifications, further education and resources are imperative to improve patient outcomes and reduce the increasing hospitalization rates related to this syndrome. As awareness grows, so too does the hope for better management options and ultimately better quality of life for those affected. For more information on their initiatives and strategies, individuals can visit www.MNK-Endo.com.

As October 14 approaches each year, the spotlight will continue to shine on HRS, urging broader recognition and catering to the needs within the community affected by this serious health condition.